# To eradicate or not? Helicobacter pylori in patients with inflammatory bowel disease: an updated systematic review and meta-analysis

**Authors:** Yuzhen Bi, Limin Zhou, Shunhai Zhou, Yan Sun, Jun Zhang

PMC · DOI: 10.3389/fmed.2026.1757356 · Frontiers in Medicine · 2026-02-03

## TL;DR

This study finds that Helicobacter pylori infection is less common in people with inflammatory bowel disease, especially Crohn's disease, suggesting a possible protective role.

## Contribution

An updated systematic review and meta-analysis reveals a strong negative association between Helicobacter pylori and inflammatory bowel disease.

## Key findings

- H. pylori infection is significantly less prevalent in IBD patients compared to controls.
- The association is strongest for Crohn’s disease and in Eastern populations.
- The findings are robust despite high heterogeneity and no significant publication bias.

## Abstract

The management of Helicobacter pylori (H. pylori) in patients with inflammatory bowel disease (IBD) presents a common clinical dilemma. While standard guidelines recommend H. pylori eradication to prevent gastric pathology, emerging evidence suggests a potential complex relationship with IBD. This study aims to critically evaluate this relationship through an updated systematic review and meta-analysis to inform clinical decision-making.

A comprehensive literature search on four major databases, PubMed, Embase, Medline, and Web of Science, was conducted, and all records before July 10th, 2025, were retrieved for screening. Pooled odds ratios (OR) with 95% confidence intervals (CIs) were calculated using STATA 18 software and a random-effects model (Restricted Maximum Likelihood, REML). Subgroup analyses, meta-regression, heterogeneity, sensitivity, and publication bias analyses were performed.

Analysis of 44 studies involving 14,100 IBD patients and 291,352 controls revealed a significantly lower prevalence of H. pylori infection in IBD patients compared to controls (13.48% vs. 10.87%; OR: 0.43, 95% CI: 0.35–0.53, p < 0.01). This negative association was particularly strong for Crohn’s disease (OR: 0.36, 95%CI: 0.28–0.45) and in Eastern populations (OR: 0.34, 95%CI: 0.26–0.40). Heterogeneity was high (I2 = 84.93%), but sensitivity analysis confirmed the robustness of the findings. No significant publication bias was detected.

This meta-analysis demonstrates a significant negative association between H. pylori infection and IBD, particularly in patients with Crohn’s disease and those of Eastern population. Furthermore, H. pylori may exert a potential immunomodulatory role in IBD.

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024567688, CRD42024567688.

## Linked entities

- **Diseases:** inflammatory bowel disease (MONDO:0005265), Crohn’s disease (MONDO:0005011)
- **Species:** Helicobacter pylori (taxon 210)

## Full-text entities

- **Genes:** IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, CagA [NCBI Gene 48200769], IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}
- **Diseases:** allergy (MESH:D004342), IBD (MESH:D015212), Enteritis (MESH:D004751), Ileitis (MESH:D007079), Idiopathic Proctocolitis (MESH:D003093), chronic gastritis (MESH:D005756), eczema (MESH:D004485), HP (MESH:C537262), Ulcerative (MESH:D014456), gastric mucosa-associated lymphoid tissue (MALT) lymphoma (MESH:D018442), immunological abnormalities (MESH:D007154), upper gastrointestinal disorders (MESH:D005767), peptic ulcer disease (MESH:D010437), MC (MESH:D046728), Colitis (MESH:D003092), CD (MESH:D003424), infected (MESH:D007239), gastric cancer (MESH:D013274), autoimmune diseases (MESH:D001327), obesity (MESH:D009765), H pylori infection (MESH:D016481), atopic (MESH:C566404), gastrointestinal symptoms (MESH:D012817), chronic intestinal inflammation (MESH:D007249), asthma (MESH:D001249), dysbiosis (MESH:D064806)
- **Chemicals:** steroids (MESH:D013256), carbohydrates (MESH:D002241), urea (MESH:D014508), 5-aminosalicylates (MESH:D019804)
- **Species:** Hepacivirus P (species) [taxon 2202225], Homo sapiens (human, species) [taxon 9606], Helicobacter pylori (species) [taxon 210]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12910842/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12910842/full.md

## References

81 references — full list in the complete paper: https://tomesphere.com/paper/PMC12910842/full.md

---
Source: https://tomesphere.com/paper/PMC12910842